Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Lung cancer mortality and years of potential life lost among males and females over six decades in a country with high smoking prevalence: an observational study

Authors: Ulrich John, Monika Hanke

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Little is known about sex-specific trends in lung cancer mortality and years of potential life lost (YPLL) attributable to lung cancer over more than five decades. The aim of the present study was to describe mortality and YPLL due to lung cancer over 61 years of observation in a country with a high smoking prevalence.

Methods

We obtained data on trends in lung cancer mortality, population-level vital statistics, sales of taxed tobacco products, and survey data on smoking behavior among the German population. We then undertook joinpoint regression analyses to determine sex-specific trends in lung cancer mortality and YPLL.

Results

Rates of lung cancer mortality and rates of lung cancer among all causes of death increased more among females than among males. Although YPLL among females increased from 6.6 in 1952 to 11.3 in 2012, this figure was found to have decreased from 7.3 to 4.4 among males in the same period. Sales of tobacco subject to tax increased from 1,509 cigarette equivalents per resident aged 15 or older in 1952 to 2,916 in 1976 — after which there was a decline. The prevalence of current smoking among females aged 35 years or older remained stable between 17.9 and 18.9 % in the period from 1989 to 2009. Among males in the same age group, however, prevalence decreased from 36.7 % in 1989 to 27.5 % in 2009.

Conclusions

Lung cancer mortality and YPLL among females increased over the six decades studied. Women should be more considered in smoking policies.
Literature
1.
Bosetti C, Malvezzi M, Rosso T, Bertuccio P, Gallus S, Chatenoud L, et al. Lung cancer mortality in European women: trends and predictions. Lung Cancer. 2012;78(3):171–8.CrossRefPubMed
2.
Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25(8):1650–6.CrossRefPubMed
3.
Torre LA, Siegel RL, Ward EM, Jemal A. International variation in lung cancer mortality rates and trends among women. Cancer Epidemiol Biomarkers Prev. 2014;23(6):1025–36.CrossRefPubMed
4.
Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100(23):1672–94.CrossRefPubMedPubMedCentral
5.
US Burden of Disease Collaborators. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591–608.CrossRef
6.
7.
Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds. Br J Cancer. 2005;92(2):241–5.PubMedPubMedCentral
8.
9.
Baliunas D, Patra J, Rehm J, Popova S, Kaiserman M, Taylor B. Smoking-attributable mortality and expected years of life lost in Canada 2002: Conclusions for prevention and policy. Chronic Dis Can. 2007;27(4):154–62.PubMed
10.
World Health Organization. Life expectancy at birth both sexes: 2012. Geneva: World Health Organization; 2014.
11.
US Department of Health and Human Services. The health consequences of smoking - 50 years of progress. A report of the surgeon general. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
12.
Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351–64.CrossRefPubMedPubMedCentral
13.
Vollset SE, Tverdal A, Gjessing HK. Smoking and deaths between 40 and 70 years of age in women and men. Ann Intern Med. 2006;144(6):381–9.CrossRefPubMed
14.
Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second century. Tob Control. 2012;21(2):96–101.CrossRefPubMed
15.
Deutsches Institut für Medizinische Dokumentation und Information [German Institute of Medical Documentation and Information]. ICD-10-WHO. German Version. Köln: Deutsches Institut für Medizinische Dokumentation und Information [German Institute of Medical Documentation and Information]; 2014.
16.
Federal Statistical Office. Fachserie 14, Reihe 9.1.2; Tabakgewerbe Jahre 1952–1990 [tobacco trade, years: 1952–1990]. Wiesbaden: Federal Statistical Office; 1991.
17.
Federal Statistical Office. Fachserie 14, Reihe 9.1.1 Absatz von Tabakwaren Jahre 1991–2012 [tobacco sales years: 1991–2012]. Wiesbaden: Federal Statistical Office; 2014.
18.
19.
Federal Statistical Office. Microcensus 1989, 1995, 1999, 2003, 2005, 2009. Scientific use files including random samples of 70 % of respondents. Wiesbaden: Federal Statistical Office; 2012.
20.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.CrossRefPubMed
21.
National Cancer Institute. Joinpoint regression program. Version 4.1.1.3. Bethesda, MD: National Cancer Institute; 2014.
22.
Danielsson M, Gilljam H, Hemstrom O. Tobacco habits and tobacco-related diseases: Health in Sweden: The National Public Health Report 2012. Chapter 10. Scand J Pub Health. 2012;40(9 Suppl):197–210.CrossRef
23.
Engholm G, Ferlay J, Christensen N, Johannesen T, Khan S, Køtlum J, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 6.1 (25.04.2014). Copenhagen: Association of the Nordic Cancer Registries, Danish Cancer Society; 2014.
24.
Wienecke A, Barnes B, Lampert T, Kraywinkel K. Changes in cancer incidence attributable to tobacco smoking in Germany, 1999–2008. Int J Cancer. 2014;134(3):682–91.CrossRefPubMed
25.
Joossens L, Raw M. The Tobacco Control Scale 2013 in Europe. Brussels: Association of European Cancer Leagues; 2014.
26.
Polednak AP. Trends in incidence rates of tobacco-related cancer, selected areas, SEER Program, United States, 1992–2004. Prev Chronic Dis. 2009;6(1):A16.PubMed
27.
Polednak AP. Lung cancer incidence trends by histologic type in areas of California vs. other areas in the Surveillance, Epidemiology and End Results Program. Cancer Epidemiol. 2009;33(5):319–24.CrossRefPubMed
28.
Pinkhasov RM, Wong J, Kashanian J, Lee M, Samadi DB, Pinkhasov MM, et al. Are men shortchanged on health? Perspective on health care utilization and health risk behavior in men and women in the United States. Int J Clin Pract. 2010;64(4):475–87.CrossRefPubMed
29.
Zentrum für Krebsregisterdaten. Lungenkrebs [lung cancer]. Berlin: Robert-Koch-Institut; 2014.
30.
Davis VN, Lavender A, Bayakly R, Ray K, Moon T. Using current smoking prevalence to project lung cancer morbidity and mortality in Georgia by 2020. Prev Chronic Dis. 2013;10:E74.CrossRefPubMedPubMedCentral
31.
Pauly JL, Mepani AB, Lesses JD, Cummings KM, Streck RJ. Cigarettes with defective filters marketed for 40 years: what Philip Morris never told smokers. Tob Control. 2002;11 Suppl 1:I51–61.CrossRefPubMedPubMedCentral
Metadata
Title
Lung cancer mortality and years of potential life lost among males and females over six decades in a country with high smoking prevalence: an observational study
Authors
Ulrich John
Monika Hanke
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1807-7

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Erratum

Erratum to: ComOn Coaching: study protocol of a randomized controlled trial to assess the effect of a varied number of coaching sessions on transfer into clinical practice following communication skills training

Research article

Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma

Research article

Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation

Research article

Dual role of CD44 isoforms in ampullary adenocarcinoma: CD44s predicts poor prognosis in early cancer and CD44ν is an indicator for recurrence in advanced cancer

Research article

Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy

Research article

Secreted frizzled-related protein promotors are hypermethylated in cutaneous squamous carcinoma compared with normal epidermis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits